Core Insights - Robertet is investing in Aethera Biotech to enhance its capabilities in plant-based biotechnologies, with a joint venture planned to be 50-50 owned by both companies in the long term [1][2] Group 1: Investment Details - The investment in Aethera Biotech will occur in two phases over three years, contingent on undisclosed market conditions [1] - Financial terms of the deal have not been disclosed [1] Group 2: Company Background - Aethera Biotech, founded in 2016 and based in Camisano Vicentino, Italy, specializes in producing active ingredients for the cosmetic and health markets through cell multiplication processes [3] - Aethera is a subsidiary of Cereal Docks Group, which focuses on primary agro-food transformation [3] Group 3: Biotechnology Strategy - The partnership aims to develop advanced cosmetic active ingredients, reflecting a targeted biotech strategy [2] - Aethera's proprietary CROP platform allows for the secure production of natural extracts in controlled conditions, independent of external factors [4] Group 4: Environmental Impact - The CROP platform significantly reduces environmental impact and offers a sustainable alternative to traditional production methods, embodying the concept of 'Augmented Naturality' [5] - This collaboration enables Robertet to strengthen its biotechnology expertise and secure sustainable access to innovative natural ingredients [6] Group 5: Leadership and Future Outlook - The joint venture aligns with Robertet's ambition to reinforce its leadership in natural ingredients and explore new pathways for innovation and growth [7]

Core Viewpoint - The Indian Hotels Company (IHCL) experienced a decline in share price despite reporting strong quarterly results for Q3FY26, with a net profit increase of 50.2% year-on-year [1][3]. Financial Performance - IHCL reported a net profit of ₹954.2 crore for Q3FY26, up from ₹635.2 crore in the same quarter last year [3]. - Revenue from operations grew 12.2% year-on-year to ₹2,842 crore, compared to ₹2,533 crore in the previous year [3]. - Earnings before interest, tax, depreciation, and amortisation (EBITDA) increased by 11.9% to ₹1,076 crore, with EBITDA margins remaining flat at 37.9% [4]. Management Commentary - The managing director highlighted that Q3FY26 marked the 15th consecutive quarter of record performance, with consolidated revenue reaching ₹2,900 crore, a 12% increase from the previous year [5]. - The hotel segment alone generated revenue of ₹2,579 crore, leading to the best-ever quarterly EBITDA of ₹1,050 crore [6]. Strategic Initiatives - IHCL signed 239 new agreements, expanding its portfolio to 617 hotels, and opened 120 hotels through strategic partnerships and acquisitions [7]. - The company acquired a controlling stake in Atmantan and a 51% stake in Brij, along with a 51% acquisition in ANK & Pride Hospitality [7]. Analyst Insights - Analysts from Axis Securities maintain a positive outlook for IHCL, citing demand consistently outpacing supply and projecting double-digit revenue growth for the full year [8]. - The brokerage expects new business segments, including Ginger and Qmin, to contribute 25% of revenues by FY27 [9]. - IHCL plans disciplined capital allocation with an annual capital expenditure of around ₹1,000 crore, fully funded through internal accruals [10]. Future Outlook - With a strong pipeline of 30,200 keys and expansion into high-margin segments, IHCL is positioned to double its consolidated revenue and expand its portfolio to over 700 hotels by 2030 [11]. - Motilal Oswal Financial Services anticipates sustained momentum driven by a robust room addition pipeline and favorable demand-supply dynamics [12].